GADODIAMIDE HYDRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H26N5O8.Gd.3H2O
Molecular Weight	627.7
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.O.O.[Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O

InChI

InChIKey=WYKPQCVMUQQKCL-UHFFFAOYSA-K

InChI=1S/C16H29N5O8.Gd.3H2O/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;;;;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);;3*1H2/q;+3;;;/p-3

HIDE SMILES / InChI

Description
Sources: http://www3.gehealthcare.com.au/en-au/products/categories/contrast_media

Gadodiamide is a nonionic, low-osmolar gadolinium-based contrast agent for diagnostic contrast-enhanced magnetic resonance imaging (MRI).

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Contrast agent for MRI 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022066s007,020123s043lbl.pdf	Diagnostic		Approved 8429	OMNISCAN Approved Use Diagnostic magnetic resonance imaging (MRI) indicated for intravenous use to visualize lesions with abnormal vascularity in the brain, spine, and associated tissues; facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space. Launch Date 1993

T_1/2

Value	Dose	Co-administered	Analyte	Population
77.8 min DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022066lbl.pdf	0.1 mmol/kg single, intravenous dose: 0.1 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:		GADODIAMIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
100% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022066lbl.pdf	0.1 mmol/kg single, intravenous dose: 0.1 mmol/kg route of administration: Intravenous experiment type: SINGLE co-administered:		GADODIAMIDE unknown	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201277Orig1s000PharmR.pdf#page=53 Page: 53.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:37333	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:37333
ChemicalBook	CB1501382	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1501382
MolPort	MolPort-046-417-370	https://www.molport.com/shop/molecule-link/MolPort-046-417-370
eMolecules	10135332	https://www.emolecules.com/cgi-bin/more?vid=10135332

PubMed

Title	Date	PubMed
Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats.	1998 Sep	9763378
Gadolinium arteriography complicated by acute pancreatitis and acute renal failure.	2001 Mar	11287523
Gadodiamide-associated nephrogenic systemic fibrosis.	2007 Jun	17515359
Case-control study of gadodiamide-related nephrogenic systemic fibrosis.	2007 Nov	17483196
Nephrogenic systemic fibrosis: possible association with a predisposing infection.	2008 Apr	18356457
Semi-quantification of endolymphatic size on MR imaging after intravenous injection of single-dose gadodiamide: comparison between two types of processing strategies.	2013 Dec 25	24172793
IV Administered Gadodiamide Enters the Lumen of the Prostatic Glands: X-Ray Fluorescence Microscopy Examination of a Mouse Model.	2015 Sep	26295667
T1 Signal-Intensity Increase in the Dentate Nucleus after Multiple Exposures to Gadodiamide: Intraindividual Comparison between 2 Commonly Used Sequences.	2016 Aug	27032972
Cochlear Lymph Fluid Signal Increase in Patients with Otosclerosis after Intravenous Administration of Gadodiamide.	2016 Jul 11	26841857
Investigation of the ototoxicity of gadoteridol (ProHance) and gadodiamide (Omniscan) in mice.	2016 Nov	27315460
Signal intensity change on unenhanced T1-weighted images in dentate nucleus following gadobenate dimeglumine in patients with and without previous multiple administrations of gadodiamide.	2016 Nov	26911888

Patents

Sample Use Guides

In Vivo Use Guide

0.2 mL/kg (CNS), 0.1 mL/kg (kidney), 0.2 mL/kg (Intrathoracic, intra-abdominal, and pelvic cavities)

Route of Administration: Intravenous

In Vitro Use Guide

Unknown

Name

Type

Language

GADODIAMIDE HYDRATE

Common Name

English

GADODIAMIDE HYDRATE [JAN]

Common Name

English

AQUA(N-N'-BIS(2-((CARBOXYMETHYL)((METHYLCARBAMOYL)METHYL)AMINO)ETHYL)GLYCINATO(3-))GADOLINIUM HYDRATE

Common Name

English

GADODIAMIDE TRIHYDRATE

Common Name

English

GADODIAMIDE HYDRATE [EP MONOGRAPH]

Common Name

English

Code System Code Type Description

FDA UNII

0RPE15QPL0